The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.
The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
Data from MMRF's Immune Atlas will be included in its recently launched CureCloud, a registry of clinical, genomic, and EHR data from multiple myeloma patients.
The former head of the Icahn Institute for Genomics and Multiscale Biology discussed how data quality can improve biomedical research and inform precision medicine.
The grant is part of a CZI effort to fund research projects supporting the Human Cell Atlas, which is building a reference atlas of all human cell types.
